Alembic Charts China Plans And Sees Price Cuts As No Dampener
Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.
You may also be interested in...
With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.
Sun Pharma continues to build its global specialty business with an increasing focus on China and Japan. As it revealed first-quarter results, the company announced a licensing deal with CMS and a new leader for its operations in China.
Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.